Novartis AG (NYSE:NVS) is one of the top cheap pharmaceutical stocks to buy now. In a report released on August 1, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NYSE:NVS) with a price target of CHF108.00.
A doctor holding a microscope in front of a laboratory sample of healthcare products.
The rating update followed Novartis AG’s release of fiscal Q2 2025 results on July 17, reflecting a strong quarter with core operating income growth and double-digital sales.
Novartis AG reported $14.1 billion in net sales for the quarter, with volume contributing 12 percentage points to growth.
Operating income rose to $4.9 billion, primarily driven by higher net sales. Net income also grew to $4.0 billion, attributed to higher operating income.
Novartis AG further reported that core operating income margin was 42.2% of net sales, growing 2.6 percentage points.
Headquartered in Basel, Switzerland, Novartis AG develops, markets, and manufactures a range of healthcare products. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
